Christine Duncan, MD, Dana-Farber Cancer Institute
Articles by Christine Duncan, MD, Dana-Farber Cancer Institute
Narsoplimab: The Phase 2 Trial
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Samer Khaled, MD reviews the design, results, and practical implications of the pivotal phase 2 trial of narsoplimab, a MASP-2 targeted monoclonal antibody under investigation for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation.
Role of Leptin in the MASP-2 Pathway
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Jeffrey Laurence, MD, discusses the role of leptin in the MASP-2 pathway as well as coagulation and complement pathways.
TA-TMA Treatment: Alternative Medications
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine The panel reviews therapeutic options for managing transplant-associated thrombotic microangiopathy and the challenges associated with currently existing agents.
Practical Experience in TA-TMA Interventions
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Experts in the field of hematopoietic stem cell transplantation provide their views and experiences with various interventions for managing transplant-associated thrombotic microangiopathy.
Interventions Used for TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Jeffrey Laurence, MD, reviews the available interventions used to mitigate or treat transplant-associated thrombotic microangiopathy.
Challenges of Accurate Diagnosis of TA-TMA After Hematopoietic Stem Cell Transplant
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine A panel of experts recall the challenges of accurate early detection of transplant-associated thrombotic microangiopathy and its importance for improved patient outcomes.
Relationship Between TA-TMA Development and GVHD
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine The panel considers the development, morbidity, and survival of transplant-associated thrombotic microangiopathy associated with GVHD (graft-versus-host disease).
Risk Factors Associated With TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Jeffrey Laurence, MD, reviews the risk factors for developing transplant-associated thrombotic microangiopathy, and the panel discusses how risk affects their decision to change or modify treatment regimens.
Uncontrolled Versus Self-Limited TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Parameswaran Hari, MD, and Christine Duncan, MD, discuss the differences between uncontrolled vs self-limited transplant-associated thrombotic microangiopathy.
Time Frame for Development of TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.
Criteria for Diagnosing TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine A panel of experts in hematopoietic stem cell transplantation examine their personal experience in the incidence of transplant-associated thrombotic microangiopathy in the adult and pediatric populations and the criteria used to diagnose.
Incidence of TA-TMA
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Parameswaran Hari, MD, reviews challenges in defining the incidence of transplant-associated thrombotic microangiopathy; an expert panel comments on the volume of autologous transplants performed in expert centers.
Overview of Transplant-Associated Thrombotic Microangiopathy (TA-TMA)
BySamer Khaled, MD, City of Hope,Christine Duncan, MD, Dana-Farber Cancer Institute,Parameswaran Hari, MD, MRCP, MS, Medical College of Wisconsin,Jeffrey Laurence, MD, Weill Cornell Medicine Jeffrey Laurence, MD, provides an overview of transplant-associated thrombotic microangiopathy (TA-TMA), the associated risk factors, and the role of the complement pathway in TA-TMA development.
